Clinical trial NCT01703624 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: glycopyrronium bromide
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female age 40-75 years, inclusive

          -  A clinical diagnosis of moderate to severe COPD (GOLD guidelines)

          -  Current smokers or ex-smokers with at least 10-pack year smoking history

          -  Post-bronchodilator FEV1/FVC ratio < 70 % at Screen

          -  Post-bronchodilator FEV1 ≥ 40 % to < 80 % of predicted at Screen

          -  Demonstrated to be responsive to ipratropium (defined as at least an 100ml increase in
             FEV1 following ipratropium 80 µg)

          -  Ability to perform acceptable spirometry (ATS/ERS guidelines)

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  Females who are pregnant or lactating at the Screening Visit, or if of childbearing
             potential not using an acceptable means of birth control throughout the study (defined
             in protocol)

          -  Current evidence or recent history of any clinically significant disease (other than
             COPD) or abnormality in the opinion of the Investigator that would put the subject at
             risk or which would compromise the quality of the study data (defined in protocol)

          -  Recent history of hospitalisation due to an exacerbation of airway disease within
             three months prior to the Screening Visit or randomisation

          -  Need for increased treatments of COPD within six weeks prior to the Screening Visit or
             randomisation

          -  Primary diagnosis of asthma

          -  Prior lung volume reductions surgery or history of chest/lung irradiation

          -  Regular use of daily oxygen therapy

          -  Use of systemic steroids within three months prior to the Screening Visit or during
             the run-in period

          -  Respiratory tract infection within six weeks prior to the Screening Visit.

          -  History of tuberculosis, bronchiectasis or other non-specific pulmonary disease

          -  History of urinary retention or bladder neck obstructive type symptoms

          -  History of narrow-angle glaucoma

          -  Clinically significant abnormal ECG

          -  Positive Hepatitis B antigen or positive Hepatitis C antibody

          -  Positive screening test for HIV antibodies

          -  Current evidence or history of excessive use or abuse of alcohol in the opinion of the
             Investigator

          -  Current evidence or history of abusing legal drugs or use of illegal drugs or
             substances in the opinion of the Investigator

          -  Donation of 450 ml or more of blood within eight weeks of the Screening Visit

          -  History of hypersensitivity or intolerance to aerosol medications

          -  Participation in another investigational drug study where drug was received within 30
             days prior to the Screening Visit.

          -  Inability to comply with study procedures or with study treatment intake, including
             inability to be trained and/or inability to demonstrate good inhaler technique with
             Vitalograph AIM